ProMIS Neurosciences Appoints Internationally Recognized Neuroscientist Dr. Cheryl Wellington to its Scientific Advisory Board
27 janv. 2022 07h00 HE
|
ProMIS Neurosciences Inc.
TORONTO, Ontario and CAMBRIDGE, Mass., Jan. 27, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development...
ProMIS Neurosciences Announces Antibody Program for Schizophrenia Therapy and Recruitment of Dr. Carsten Korth to its Scientific Advisory Board
18 janv. 2022 07h00 HE
|
ProMIS Neurosciences Inc.
TORONTO, Ontario and CAMBRIDGE, Mass., Jan. 18, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of...
ProMIS Neurosciences to Participate in the Biotech Showcase 2022 Virtual Panel Discussion: Aduhelm Stimulating the Next Generation of Alzheimer’s Treatment
07 janv. 2022 07h00 HE
|
ProMIS Neurosciences Inc.
TORONTO, Ontario and CAMBRIDGE, Mass., Jan. 07, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of...
ProMIS Neurosciences to Participate in H.C. Wainwright BioConnect 2022 Virtual Conference
06 janv. 2022 07h30 HE
|
ProMIS Neurosciences Inc.
TORONTO, Ontario and CAMBRIDGE, Mass., Jan. 06, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of...
ProMIS Neurosciences Issues Chairman’s Memorandum
16 déc. 2021 07h30 HE
|
ProMIS Neurosciences Inc.
TORONTO, Ontario and CAMBRIDGE, Mass., Dec. 16, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of...
ProMIS Neurosciences Shareholders Approve Special Resolution
02 déc. 2021 07h00 HE
|
ProMIS Neurosciences Inc.
TORONTO and CAMBRIDGE, Mass., Dec. 02, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (TSX: PMN) (OTCQB: ARFXF) (the “Company”), a biotechnology company focused on the discovery and development...
A Second Independent Proxy Advisor, ISS, Recommends Promis Neurosciences Shareholders Vote for the Share Consolidation
17 nov. 2021 07h00 HE
|
ProMIS Neurosciences Inc.
For any questions, please contact ProMIS’ proxy solicitation agent, Laurel Hill Advisory Group at 1-877- 452-7184 (+1-416-304-0211 outside North America) or email assistance@laurelhill.com. ...
ProMIS Neurosciences Announces Third Quarter 2021 Results
12 nov. 2021 07h00 HE
|
ProMIS Neurosciences Inc.
TORONTO and CAMBRIDGE, Mass., Nov. 12, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF) (“ProMIS or the Company”), a biotechnology company focused on the discovery and...
Glass Lewis Recommends ProMIS Neurosciences Shareholders Vote for the Share Consolidation at the Upcoming Special Meeting
02 nov. 2021 07h00 HE
|
ProMIS Neurosciences Inc.
For any questions, please contact ProMIS’ proxy solicitation agent, Laurel Hill Advisory Group at 1-877- 452-7184 (+1-416-304-0211 outside North America) or email assistance@laurelhill.com. TORONTO...
ProMIS Neurosciences Announces Update to Senior Management Team
22 oct. 2021 07h00 HE
|
ProMIS Neurosciences Inc.
TORONTO and CAMBRIDGE, Mass., Oct. 22, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN); (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody...